Abstract Though the role of Estrogen Receptor (ER)a in breast cancer has been studied extensively, there is little consensus about the role of alternative ER isoform ERb in breast cancer biology. ERb has significant sequence homology to ERa but is located on a different chromosome and maintains both overlapping and unique functional attributes. Five variants exist, resulting from alternative splicing of the C-terminal region of ERb. The relevance of ERb variants in breast cancer outcomes and response to therapy is difficult to assess because of conflicting reports in the literature, likely due to variable methods used to assess ERb in patient tumors. Here, we quantitatively assess expression of ERb splice variants on over 2,000 breast cancer patient samples. Antibodies against ERb variants were validated for staining specificity in cell lines by siRNA knockdown of ESR2 and staining reproducibility on formalin-fixed paraffin-embedded tissue by quantitative immunofluorescence (QIF) using AQUA technology. We found antibodies against splice variants ERb1 and ERb5, but not ERb2/cx, which were sensitive, specific, and reproducible. QIF staining of validated antibodies showed both ERb1 and ERb5 QIF scores, which have a normal (bell shaped) distribution on most cohorts assessed, and their expression is significantly associated with each other. Extensive survival analyses show that ERb1 is not a prognostic or predictive biomarker for breast cancer. ERb5 appears to be a context-dependent marker of worse outcome in HER2-positive and triple-negative patients, suggesting an unknown biological function in the absence of ERa.
Introduction
Estrogen Receptor (ER) b was first identified in rat prostate in 1996 and, like ERa, is a nuclear hormone receptor that dimerizes in the presence of estrogen, binds sequencespecific estrogen response elements present in DNA, and subsequently recruits transcriptional activators and repressors to nearby genes [1] . The transcriptional profiles of cell lines expressing ERa and/or ERb in the presence of estrogen have been extensively studied and generally show some overlapping targets of the two ERs, though differences in the DNA binding domain as well as the activation function domains of the two ERs likely account for the different, seemingly antagonistic role of ERb to ERa signaling [2] [3] [4] [5] [6] . Variants of both ERs resulting from alternative splicing have been identified over the years, and their ability to alter cellular response to estrogen in vitro suggests that estrogen signaling is not solely carried out by full-length ERa [7] [8] [9] [10] [11] . The ERb variants ERb1, ERb2/cx, and ERb5 represent proteins that are identical exclusive of the C-terminus. ERb2/cx and ERb5 both have truncations that alter ligand binding capabilities though all three ERb variants can heterodimerize with ERa and potentially alter estrogen signaling.
For decades, ERa has been an essential, though imperfect, breast cancer biomarker in the clinic for initial diagnosis and subsequent therapeutic decision-making. The selective estrogen receptor modulator tamoxifen is given to patients whose tumors express ERa, but not all of these patients will respond initially and many will eventually relapse [12] [13] [14] . Despite the discovery of ERb nearly 10 years ago, the relevance of its expression in breast cancer to prognosis and response to therapy is still uncertain. The literature examining ERb correlations with clinicopathological tumor characteristics, survival, and response to therapy is astoundingly discordant [15] . Possible explanations for these discrepancies are non-specificity of reagents for the different splice variants of ERb, small sample sizes, the lack of a standardized method of measurement, or many other issues inherent in small discovery-based studies. One major limitation to evaluating ERb protein levels is a lack of commercially available antibodies specific to the alternatively spliced forms. As such, there is no consensus on the usefulness of ERb in clinical diagnosis of breast cancer. While it could potentially provide novel insight in predicting response to endocrine therapy, there is no high level data supporting either clinical validity or clinical utility.
In this study, we have set out to clarify the relevance of ERb as a breast cancer biomarker for prognosis and response to therapy by rigorously validating specificity and reproducibility of antibodies against the ERb variants and then quantitatively measuring their expression on thousands of patients from multiple institutions with clinical follow-up and treatment information.
Methods

Cell lines and siRNA knockdown
Cell lines MCF7-ERb1 and MCF7-ERb2 are constructs with doxycycline-inducible expression of ERb1 and ERb2/ cx constructed and shared by LC Murphy and previously described in [16] . Cells were grown on coverslips, and expression of ERb was induced with 2 lg/ml of doxycycline for 24 h then knocked down with ESR2 Stealth siRNA (Invitrogen, Cat#1299001) for 24 h. For knockdown of ERb5, A431 cells were grown on coverslips and knocked down with ESR2 siRNA as above. Immunofluourescent staining was performed on coverslips briefly as follows; cells were fixed in 3.7 % formaldehyde, permeabilized in 0.2 % TritonX-100 then blocked in 2 % BSA. To assess staining in cell lines grown on coverslips, primary antibodies were incubated overnight at 4°C at dilutions of 1:500, 1:100, and 1:250 for ERb1 (ThermoScientific, PPG5/10), ERb2/cx (Serotec, 57/3), and ERb5 (Serotec, 5/25), respectively. 1 h secondary antibody Alexa546-conjugated goat anti-mouse (Life Technologies) diluted 1:500 in BSA was followed by DAPI stain.
Quantitative immunofluorescent staining
Tissue microarrays (TMAs) were deparaffinized for 20 min at 60°C then soaked in xylene twice for 20 min each. Slides were rehydrated in two 1 min washes in 100 % ethanol followed by one wash in 70 % ethanol and finally rinsed in streaming tap water for 5 min. Antigen retrieval was performed in sodium citrate buffer, pH6 in the PT module from LabVision. Endogenous peroxidases were blocked by 30 min incubation in 2.5 % hydrogen peroxide in methanol. Nonspecific antigens were then blocked by 30 min incubation in 0.3 % BSA in TBST. Primary antibodies were prepared diluted to 1:500 (ERb1; Thermoscientific PPG5/10) and 1:250 (ERb5; Serotec 5/25) combined with 1:100 pan-cytokeratin (Dako, Cat#Z062201-2) in 0.3 % BSA in TBST and incubated at 4°C overnight. Primary antibodies were followed by incubation with Alexa 546-conjugated goat anti-rabbit secondary antibody (Life Technologies, Cat#A-11010) diluted 1:100 in mouse EnVision reagent (Dako, Cat#K400111-2) for 1 h. Signal was amplified with Cy5-Tyramide (Perkin Elmer, Cat#SAT705A001EA) for 10 min and then slides were mounted with ProlongGold ? DAPI (Life Technologies, Cat#P36931). Immunofluorescence was quantified using AQUA. Briefly, fluorescent images of DAPI, Cy3 (Alexa 546-cytokeratin), and Cy5 (target-ERb1 or ERb5) for each TMA spot were collected. Image analysis was carried out using AQUAnalysis software (Genoptix), which uses the cytokeratin stain to generate an epithelial tumor mask. The AQUA score is calculated by dividing the sum of target pixel intensities by the area of the compartments within which they were measured [17, 18] .
Patient cohorts
This study includes four cohorts of archived breast cancer cases, constructed into formalin-fixed, paraffin-embedded [19] [20] [21] [22] . Clinical variables are shown in Table 1 as reported by the individual institutions from 
Results
Identification of specific and reproducible antibodies to ERb1 and ERb5
Antibodies against ERb splice variants were validated by testing their specificity and reproducibility measured by quantitative immunofluorescence (QIF) (Fig. 1) . Specificity of ERb1 and ERb5 was validated using siRNA knockdown of ESR2 in cell lines. For ERb1, MCF-7 cells with doxycycline-inducible expression of Xpress-tagged ERb1 were treated with ESR2 siRNA and staining of ERb1 assessed on cells grown on coverslips, showing an increase in fluorescence when ERb1 expression is induced with doxycycline and a substantial decrease when knocked down with ESR2 siRNA (Fig. 1a, left) . Similar experiments were done with MCF-7 cells with doxycyclineinducible expression of Xpress-tagged ERb2/cx, but the antibody used showed no difference in fluorescence in the siRNA knockdown despite successful knockdown of ERb2/cx, as visualized using an anti-Xpress antibody (data not shown). Thus, the ERb2 antibody is nonspecific and was not used further (Fig. 1b) . To validate an ERb5 antibody, we used A431 cells, which showed moderate expression of ERb5 on a TMA with cell line histospots. Staining of ERb5 on A431 cells grown on coverslips showed corresponding loss of fluorescence in the cells treated with ESR2 siRNA (Fig. 1c, left) . Reproducibility of QIF of ERb1 and ERb5 antibodies on a set of breast cancer control cases showed reproducible staining, with R 2 [ 0.8 on TMAs of serial cut sections (Fig. 1a, c; right) . Table 1 for the clinicopathologic characteristics of the four cohorts. With the exception of the NCI-PBCS cohort, each ERb was assessed in two-fold redundancy, and reproducibility of the QIF assay was assessed with a control TMA consisting of 40 breast cancer histospots with known levels of ERb1 and ERb5 expression. The distributions of QIF scores of ERb1 and ERb5 on Yale cohort 1, Yale cohort 2, and the Toronto Cohort show similar normal distributions, though for both forms of ERb, the distribution on the node-negative Toronto Cohort is skewed to the left, showing a greater proportion of lower QIF scores (Fig. 2a-c left and middle panels). Nuclear ERb5 staining was present in nearly all cases in every cohort, while ERb1 showed both nuclear and/or cytoplasmic staining in approximately 70 % of cases (data not shown). Linear regression and SpearmanRank correlation of ERb1 and ERb5 on all three cohorts show a tightly correlated expression (Yale Cohort 1 Rho = 0.572; Yale Cohort 2 Rho = 0.531; Toronto Cohort Rho = 0.297), though markedly less so in the Toronto Cohort (Fig. 2a-c, right panels) .
Assessment of
ERb1 and ERb5 by QIF on four breast cancer cohorts Both ERb1 and ERb5 expression by QIF was assessed on 3 breast cancer cohorts (Yale Cohort 1, Yale Cohort 2, and Toronto Cohort) and ERb5 on one additional cohort to validate findings (NCI-PBCS). See
ERb1 is not prognostic or predictive of response to therapy
ERb1 showed no detectable value as a biomarker for patient prognosis or predicting response to therapy in any of the three cohorts examined. Parallel analyses were carried out on the same data set with ERb1 cut at the estimated visual threshold of detection by immunofluorescence with no significant results. As shown in Fig. 3b , when ERb1 QIF scores are cut at the median into low and high groups, there is no separation with relation to disease-specific survival. Literature suggests that ERb1 expression in the nuclear and cytoplasmic cellular compartments may impart differential information with regards to patient prognosis and response to therapy [24] , though the data presented here draw from quantitative scores for ERb1 expression within the entire tumor mask. Individual subcellular compartments were examined alongside total expression within the tumor mask and no differences observed. Extensive exploratory analyses were undertaken to examine ERb1 in subpopulations of patients, with particular focus on ERa? and tamoxifentreated patients, though no associations were observed in any group of patients.
ERb5 is a marginal marker of worse prognosis in total patient populations ERb5, assessed on all four breast cancer cohorts cut at the median QIF score for each patient population, shows a marginal, non-significant potential as a marker of worse prognosis on Yale Cohort 2 (Fig. 3a, (Fig. 3a, far right) . No indications of ERb5 as a prognostic marker were seen on Yale Cohort 1 or the Toronto Cohort in the total patient population.
ERb5 is prognostic in HER2? and triple-negative subsets, not luminal
The prognostic implications of ERb5 in different breast cancer subtypes were examined in Yale Cohort 1, Yale Cohort 2, and the NCI-PBCS cohort. Any hormone receptor positive, HER2-negative patients were classified as luminal, hormone receptor negative, HER2-positive patients classified as HER2-amplified and HER2-negative classified as triple negative. ERb5 expression cut at the median QIF score of the total patient population within a cohort was then assessed individually in each subtype. ERb5 shows no prognostic implications in the luminal subtypes of any of the cohorts (Fig. 4a) , rather, it appears to be a marker of worse prognosis in HER2-positive and triple-negative subsets, though these results are not significant. In both Yale Cohort 2 and the NCI-PBCS breast cancer cohort, patients received adjuvant chemotherapy, hormonal therapy, both or no adjuvant therapy. ERb5 expression in treatment subgroups reveals that ERb5 is a significant marker of worse prognosis only in patients that received adjuvant chemotherapy on the NCI-PBCS cohort, though the same trend is observed in Yale Cohort 2 (Fig. 5a, d) . Further analysis of patients that received adjuvant chemotherapy divided into breast cancer subtypes shows results similar to the overall population; ERb5 correlates with worse prognosis only in HER2? and triple-negative patients, though these observations are non-significant trends (Fig. 5b-c, e-g ).
Discussion
ERb and its alternatively spliced forms do not have a comprehensively understood role in estrogen signaling. Interest in the clinical relevance of ERb to breast cancer motivated the numerous accounts of ERb in retrospectively collected breast cancer tissue. However, discrepant results from these studies have left the question of whether or not ERb is a clinically relevant breast cancer biomarker unanswered. The presence of various splice variants with unique functionality could be one reason for these conflicting reports [7, 10, 11, 25] . However, even within those studies undertaken that delineate the different ERb splice variants there are conflicting reports [26, 27] . The general consensus regarding ERb1, derived most conclusively from cell line studies, is that it opposes ERa signaling and has tumor-suppressor function. ERb5, on the other hand, appears to oppose both ERa and ERb1 signaling [7, 25] . This rudimentary biological understanding of ERb1 and ERb5 function has not been translated to a clinically relevant tool due to varying results when the proteins are assessed in patient tumors.
We report that rigorous antibody validation is required for accurate assessment of ERb protein expression. Figure 1 shows the specificity and reproducibility of two commercially available antibodies against ERb1 and ERb5 and non-specificity of an antibody against ERb2/cx. Further, we used a quantitative approach to score staining of ERb to remove the subjectivity associated with qualitative scoring and to be able to rigorously assess reproducibility of staining to ensure a high level of quality control. Many reports in the literature draw conclusions from small patient samples with few events, resulting, perhaps, in statistically underpowered data that have likely led to much of the confusion in the ERb field. This study examines ERb1 and ERb5 expression in over 1,000 patient tumors on four different patient populations collected from the United States, Canada, and Poland, and, thus, we present the most comprehensive study to date of ERb in breast cancer patient populations.
ERb1 expression has no correlation with patient prognosis or response to therapy in any patient population examined. Studies have suggested ERb1 to act as a marker of good prognosis that can predict response to endocrine therapy in the presence or absence of ERa [24, [28] [29] [30] [31] . These results may be highly context dependent. However, this study examined four distinct populations, and ERb1 was not found to be predictive or prognostic within any of them. Our results imply that ERb1 will not apply to a broad breast cancer population as a general marker of prognosis or response to endocrine therapy.
A context-dependent, marginal effect of ERb5 expression on survival was observed. While ERb5 significantly marks worse prognosis on the NCI-PBCS cohort, the result is neither significant in multivariate analysis nor in any other patient cohort examined in this study. On two of the four cohorts examined, ERb5 is a marker of worse prognosis in HER2-positive and triple-negative subsets of patients. ERb5 shows no prognostic or predictive value in the luminal subset of patients in any cohort, a surprising result given that ERb5 has no known function apart from its ability to interfere with estrogen signaling via interaction with ERa or ERb1. Known biological functions of ERb5 require ERb1 or ERa as a binding partner; ERb5 on its own has no known ligand. Given its relevance to survival only in ERa-negative patients and lack of any indication that ERb5 effect on survival is dependent on ERb1, we speculate that ERb5 may have yet to be discovered functions in breast cancer cells. Of the two cohorts in which no correlation of ERb5 expression with survival was seen, Yale Cohort 1 consists of patients diagnosed as early as the 1960s and represents a population of larger, higher grade tumors. The other outlying cohort is the Toronto Cohort and consists only of node-negative breast cancer patients. We speculate that the lack of correlation of ERb5 with survival on these two cohorts is largely due to the difference in populations and the resulting differences in treatment.
This study has several limitations. We set out to examine ERb splice variants and were only able to examine two of the three that have been studied in the literature. We were unable to validate an antibody to ERb2/cx and thus have not performed a fully comprehensive study of the known ERb splice variants in breast cancer. Secondly, one critique of existing literature is inconsistent results, and we report the same for ERb5 association with worse outcome among four multi-institutional breast cancer cohorts examined in this study; only two of them show this trend, and, arguably, this trend could represent a random, under-powered result. We believe that the lack of any prognostic implications on the Toronto Cohort and Yale Cohort 1 reflects differences in patient populations; the Toronto Cohort is only nodenegative patients, and Yale Cohort 1 contains many patients diagnosed and treated prior to universal use of endocrine therapy for hormone receptor-positive breast cancer. This suggests that the effect of ERb5 in breast cancer is highly context dependent, only showing prognostic potential in ERa-negative or HER2-amplified populations. Finally, while we have shown that ERb5 correlates with worse outcome in breast cancer patients while ERb1 does not, a mechanism of action of ERb5 in ERa-negative patients remains elusive.
In summary, we report that ERb splice variants ERb1 and ERb5 do not predict response to endocrine therapy, but ERb5 does indicate worse outcome in patients with ERanegative and/or HER2-amplified tumors in a populationdependent manner. The results indicate that further investigation of ERb5 in an ERa-negative context is warranted, but the ultimate clinical utility of ERb5 is undetermined.
